broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K81016934-001-02-0 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 1.041463 | -0.009189 | -0.034452 | 1 | 8,634,344.964502 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000941 |
BRD-K81418486-001-44-2 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 0.959406 | -1.989491 | 0.05127 | 0.975394 | 0.21886 | null | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000941 |
BRD-K81473043-001-19-5 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 0.289164 | 6.084188 | 0.784856 | 0.715824 | 0.012907 | 0.014876 | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000941 |
BRD-K82135108-001-04-3 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 1.091596 | -0.127772 | -0.052576 | 1 | 57,068.994807 | null | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000941 |
BRD-K82818427-001-04-8 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 1.051844 | -0.275539 | -0.110111 | 1 | 3.183614 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000941 |
BRD-K83029223-001-01-3 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 1.823207 | 1.546116 | 0.537646 | 1 | 0.179831 | null | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000941 |
BRD-K83988098-001-02-0 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 0.29359 | 7.000795 | 0.626009 | 0.801487 | 0.010204 | 0.011579 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000941 |
BRD-K85402309-043-01-9 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 1.684773 | 1.226282 | 0.323427 | 1 | 0.428732 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000941 |
BRD-K85606544-001-09-1 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 0.836061 | -5.062419 | 0.296158 | 0.966759 | 0.004364 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000941 |
BRD-K86118762-001-01-8 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 1.398865 | 0.777525 | 0.315825 | 1 | 0.20782 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000941 |
BRD-K86972824-001-01-4 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 1.170674 | 6.712646 | -0.021667 | 1 | 0.020217 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000941 |
BRD-K87737963-001-06-0 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 1.075604 | 0.293313 | 0.02306 | 1 | 0.000381 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000941 |
BRD-K87782578-001-01-4 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 0.54467 | 0.622832 | 0.019242 | 0.939184 | 7.002117 | null | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000941 |
BRD-K87909389-003-03-4 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 0.18078 | 7.37282 | 0.876297 | 0.746687 | 0.497473 | 0.528685 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000941 |
BRD-K88510285-001-17-8 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 0.206823 | 3.31147 | 0.827343 | 0.661079 | 0.039595 | 0.046521 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000941 |
BRD-K89014967-001-04-3 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 1.21458 | 3.6063 | 0.356397 | 1 | 0.019581 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000941 |
BRD-K92441787-001-04-1 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 1.140723 | 1.183058 | 0.150719 | 1 | 0.024494 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000941 |
BRD-K92723993-001-17-4 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 2.322432 | 1.067256 | 0.027461 | 1 | 111.697069 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000941 |
BRD-K95142244-001-01-5 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 1.911415 | 0.639942 | 0.594559 | 1 | 0.300593 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000941 |
BRD-K96123349-236-02-8 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 1.887307 | 0.779116 | 0.714742 | 1 | 0.686811 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000941 |
BRD-K98572433-001-02-9 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 0.426912 | 3.678231 | 0.632425 | 0.910862 | 2.21264 | 3.732116 | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000941 |
BRD-K99113996-001-02-0 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 0.593595 | 0.11167 | 0.026661 | 0.839223 | 1.857532 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000941 |
BRD-K99749624-001-07-0 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 1.082013 | 0.006681 | -0.066885 | 1 | 0.463316 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000941 |
BRD-M97302542-001-04-4 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 0.792513 | 3.965833 | 0.09397 | 0.934336 | 0.463629 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000941 |
BRD-A25234499-001-19-1 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.896141 | -0.062681 | -0.00736 | 0.957124 | 0.000271 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000943 |
BRD-A70858459-001-01-7 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.143891 | 1.820166 | 0.55909 | 0.902244 | 3.571159 | 4.303106 | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000943 |
BRD-A74914197-001-02-9 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 3.641099 | 0.206617 | 0.001245 | 1 | 30,737,762.82345 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000943 |
BRD-K02113016-001-19-6 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.49762 | 0.545377 | 0.370821 | 1 | 0.195586 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000943 |
BRD-K02130563-001-11-4 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.242336 | 5.346884 | 0.235206 | 0.775003 | 0.560278 | 0.634236 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000943 |
BRD-K03390685-001-01-7 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.2458 | 0.233121 | -0.022267 | 1 | 89,554,891,097.27272 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000943 |
BRD-K03406345-001-21-1 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.82038 | 0.041241 | 0.005563 | 0.911293 | 0.141982 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000943 |
BRD-K03449891-001-08-6 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.95038 | -0.031907 | -0.003117 | 0.964588 | 109,547,827,934.65376 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000943 |
BRD-K05804044-001-18-5 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.776244 | 0.437305 | 0.059326 | 0.889692 | 0.085172 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000943 |
BRD-K06814349-304-02-7 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.570804 | 1.016463 | 0.122803 | 0.777643 | 0.065368 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000943 |
BRD-K08109215-001-06-4 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.820374 | 6.766211 | 0.359174 | 1 | 9.726173 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000943 |
BRD-K08542803-001-02-3 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.101756 | 2.877278 | 0.636468 | 0.653072 | 0.235599 | 0.254988 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000943 |
BRD-K08547377-001-04-4 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.12683 | 2.823479 | 0.746124 | 0.871353 | 2.408677 | 2.671665 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000943 |
BRD-K08703257-001-13-9 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.024028 | -0.096564 | -0.031381 | 1 | 2.496746 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000943 |
BRD-K08799216-001-05-3 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.988811 | 0.838046 | -0.028798 | 0.9945 | 0.085019 | null | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000943 |
BRD-K09951645-001-11-8 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.828895 | -0.016541 | -0.101981 | 0.915577 | 0.01582 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000943 |
BRD-K11267252-001-05-1 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.980948 | -0.178707 | 0.001312 | 0.988734 | 0.700688 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000943 |
BRD-K11630072-001-13-2 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.025099 | 3.509858 | 0.409368 | 0.979496 | 9.869991 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000943 |
BRD-K12184916-001-19-6 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.303528 | -2.012643 | 0.230944 | 1 | 0.3937 | null | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000943 |
BRD-K12343256-001-14-7 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.595062 | -0.073465 | -0.067752 | 1 | 35.471694 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000943 |
BRD-K13049116-001-04-0 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.699408 | 0.290579 | 0.203969 | 1 | 2.160349 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000943 |
BRD-K13390322-001-06-3 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.138586 | 3.036041 | 0.828711 | 0.676952 | 0.262672 | 0.292315 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000943 |
BRD-K13514097-001-04-6 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 2.151173 | 0.128651 | 0.104697 | 1 | 0.020637 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000943 |
BRD-K13662825-001-07-5 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.179243 | 6.449873 | 0.591761 | 0.689031 | 0.063332 | 0.067845 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000943 |
BRD-K14109347-001-03-4 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.635403 | 5.793154 | 0.466108 | 0.869933 | 0.313654 | null | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000943 |
BRD-K15179879-001-03-2 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.171893 | 2.491836 | 0.898484 | 0.359501 | 0.005488 | 0.006499 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000943 |
BRD-K15600710-066-05-8 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.353871 | 8.466233 | 0.783595 | 0.769873 | 0.309702 | 0.358129 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000943 |
BRD-K16730910-001-10-7 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.034974 | 1.156117 | 0.56109 | 0.852317 | 2.687464 | 2.86149 | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000943 |
BRD-K17555800-003-02-3 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.959995 | 0.266164 | 0.005747 | 0.977705 | 0.029261 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000943 |
BRD-K17610631-001-03-3 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.665094 | 0.541318 | 0.220678 | 1 | 3.364305 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000943 |
BRD-K17743125-001-08-4 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.988101 | -0.026881 | -0.046586 | 0.994603 | 0.000076 | null | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000943 |
BRD-K17894950-001-14-3 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.437499 | 0.174245 | -0.001363 | 1 | 0.715448 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000943 |
BRD-K18961567-001-01-1 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.103034 | -0.13858 | -0.056826 | 1 | 52.850425 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000943 |
BRD-K19540840-001-09-4 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | -5.0684 | 2.727719 | -0.029893 | 0.993454 | 36.633245 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000943 |
BRD-K19687926-001-04-1 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.648208 | -0.96877 | 0.153548 | 0.940848 | 0.00246 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000943 |
BRD-K19796430-001-05-6 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.849786 | -0.023269 | -0.001907 | 0.922378 | 1.39373 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000943 |
BRD-K22064724-001-01-8 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.003435 | 1.05094 | 0.367709 | 0.801844 | 1.660176 | 1.67113 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000943 |
BRD-K22822991-001-02-3 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.909093 | 0.073438 | -0.003947 | 0.965578 | 71.127407 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000943 |
BRD-K23228615-001-02-8 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.431583 | 1.544413 | 0.389351 | 1 | 0.12833 | null | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000943 |
BRD-K23984367-001-07-5 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.079606 | -4.247976 | 0.017605 | 1 | 0.352782 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000943 |
BRD-K26026438-001-01-0 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.784531 | 0.47508 | 0.095177 | 0.896652 | 0.099428 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000943 |
BRD-K28822270-001-03-7 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.947302 | -0.102443 | -0.21591 | 0.961379 | 1,870.381161 | null | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000943 |
BRD-K29905972-001-06-3 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.947796 | -1.631448 | -0.090559 | 0.957236 | 1.792528 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000943 |
BRD-K30577245-001-05-0 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.390726 | 0.523842 | 0.209411 | 0.651748 | 0.002156 | 0.039303 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000943 |
BRD-K31698212-001-02-9 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.641066 | 1.66239 | 0.193201 | 1 | 2.309397 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000943 |
BRD-K31928526-001-02-1 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.942007 | -5.47181 | -0.063407 | 0.955002 | 1.136433 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000943 |
BRD-K33379087-001-07-5 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.44308 | 0.614086 | 0.303549 | 0.679091 | 0.034326 | 1.181386 | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000943 |
BRD-K33610132-001-02-9 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.812187 | 0.488032 | -0.139791 | 0.906686 | 0.081041 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000943 |
BRD-K33622447-066-01-9 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.168625 | -0.09894 | -0.081231 | 1 | 0.005134 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000943 |
BRD-K35520305-001-16-9 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.481448 | 3.549771 | 0.056429 | 1 | 6.194383 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000943 |
BRD-K36627727-001-05-4 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.934074 | -1.846901 | 0.071213 | 0.961922 | 0.165877 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000943 |
BRD-K36788280-001-01-2 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.735766 | -0.674493 | 0.275268 | 0.902133 | 0.019825 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000943 |
BRD-K37379014-001-02-0 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.634402 | 7.101281 | 0.151105 | 0.875726 | 0.005762 | null | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000943 |
BRD-K38332599-001-01-3 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.487972 | 1.768832 | 0.197916 | 0.882671 | 1.094151 | 8.999804 | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000943 |
BRD-K38527262-300-01-0 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | -0.386487 | 1.460379 | 0.473118 | 0.904542 | 6.524168 | 4.407808 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000943 |
BRD-K38852836-001-02-1 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.149982 | 3.854785 | 0.807621 | 0.615284 | 0.030977 | 0.03398 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000943 |
BRD-K39974922-001-04-3 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.362491 | -0.837103 | 0.020229 | 0.98265 | 0.000115 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000943 |
BRD-K41859756-001-06-8 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.182492 | 1.259979 | 0.665406 | 0.503997 | 0.006903 | 0.009898 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000943 |
BRD-K42805893-001-04-9 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.994859 | -0.036107 | -0.046865 | 0.99707 | 192.906646 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000943 |
BRD-K42828737-001-03-3 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.965397 | 0.63189 | -0.001513 | 0.984675 | 0.067721 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000943 |
BRD-K42898655-001-01-8 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.819519 | 1.023448 | 0.661044 | 1 | 0.005995 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000943 |
BRD-K43389675-001-02-1 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.097656 | 4.077565 | 0.821768 | 0.746796 | 0.656651 | 0.692595 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000943 |
BRD-K44227013-001-06-4 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.304079 | 0.061806 | -0.016572 | 1 | 1.641113 | null | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000943 |
BRD-K44408410-001-17-6 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.366318 | 2.087744 | 0.449809 | 0.823323 | 0.669332 | 1.259053 | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000943 |
BRD-K44827188-001-06-0 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.97777 | -0.063153 | -0.012413 | 0.985599 | 1,304.898716 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000943 |
BRD-K46386702-001-02-1 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.021921 | -0.026254 | -0.001483 | 1 | 1,080.189627 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000943 |
BRD-K49328571-001-15-0 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.975199 | 1.42172 | 0.577996 | 1 | 0.0166 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000943 |
BRD-K49350383-001-14-5 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.535892 | 1.6884 | 0.176621 | 0.988135 | 14.725098 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000943 |
BRD-K50010139-001-01-5 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 2.123509 | 0.237742 | 0.197694 | 1 | 0.49822 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000943 |
BRD-K50168500-001-07-9 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.820679 | -7.207916 | 0.072175 | 0.884728 | 0.312335 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000943 |
BRD-K51313569-001-07-8 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.188372 | -0.029234 | -0.000271 | 1 | 0.079142 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000943 |
BRD-K51791723-003-01-7 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 1.02664 | -0.671746 | -0.047848 | 1 | 0.072535 | null | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000943 |
BRD-K51967704-001-03-6 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.128038 | 1.900989 | 0.788967 | 0.73719 | 0.537745 | 0.628282 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000943 |
BRD-K52313696-001-12-3 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.915433 | -4.402337 | -0.077021 | 0.924481 | 3.548644 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000943 |
BRD-K53414658-001-08-2 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.91839 | 8.256446 | 0.034646 | 0.97038 | 0.295334 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000943 |
BRD-K53972329-001-07-0 | ACH-000943 | RKO_LARGE_INTESTINE | MTS010 | 1 | 0.438598 | -1.090011 | -0.051997 | 0.967388 | 0.000525 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000943 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.